Alembic Pharma Q4 Review – Strong Rest Of The World Performance, API Sales Offset U.S. Decline: ICICI Direct

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Alembic Pharmaceuticals Ltd. Q4 revenue grew 6.1% year-on-year to Rs 1,280 crore with strong growth in rest of world formulations and active pharmaceutical ingredient segment being partly offset by 17.7% YoY decline in U.S. sales to Rs 475 crore.

Domestic formulations grew 4.7% YoY to Rs 358 crore.

RoW sales grew a robust 76.5% YoY to Rs 233 crore whereas API segment grew 38.1% YoY to Rs 214 crore.

Ebitda margins declined 45 basis points YoY to 26.7% with lower gross margins being mostly offset by lower employee cost.

Ebitda grew 4.3% YoY to Rs 342 crore.

Adjusted profit after tax grew 6.5% YoY to Rs 251 crore.

Click on the attachment to read the full report:

ICICI Direct Alembic Pharma Q4FY21 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Most Related Links :
thereliablenews Governmental News Finance News

Source link

Back to top button